Most U.S. cancer centers reported experiencing a shortage of at least one type of oncology drug, according to the results of a National Comprehensive Cancer Network survey.
Specifically, 86% of centers reported experiencing a shortage of at least one oncology drug, 72% reported experiencing a shortage of carboplatin and 59% reported experiencing a shortage of cisplatin.
“Everyone with cancer should have access to the best possible treatment according to the latest evidence and expert consensus guidelines,” Robert W. Carlson, MD, CEO for NCCN, said in a press release.
“Drug